


## IRAK4-IN-19

Cat. No.:	HY-150733
Molecular Formula:	C <sub>25</sub> H <sub>26</sub> F <sub>2</sub> N <sub>8</sub> O
Molecular Weight:	492.52
Target:	IRAK
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	IRAK4-IN-19 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC <sub>50</sub> value of 4.3 nM. IRAK4-IN-19 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-19 can be used for researching arthritis disease <sup>[1]</sup> .																
<b>IC<sub>50</sub> &amp; Target</b>	IRAK4 4.3 nM (IC <sub>50</sub> )																
<b>In Vitro</b>	IRAK4-IN-19 (compound 39) has inhibitory activity against LPS-induced IL23 in THP and DC with IC <sub>50</sub> s of 0.23 and 0.22 μM, respectively <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																
<b>In Vivo</b>	<p>IRAK4-IN-19 (30 mg/kg; twice daily for 21 days) completely stops arthritis development in arthritis rats at 30 mg/kg<sup>[1]</sup>.            IRAK4-IN-19 (1 mg/kg for IV, 5 mg/kg for PO, single dosage) exhibits a favorable pharmacokinetics profile<sup>[1]</sup>.            IRAK4-IN-19 (5, 15, 45 and 75 mg/kg) exhibits good efficacy in an acute mouse model for the IL-1β induced IL-6 expression, with 64% inhibition at 75 mg/kg dose, 37% inhibition at 45 mg/kg dose, 16% inhibition at 15 mg/kg dose and 9% inhibition at 5 mg/kg<sup>[1]</sup>.            MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Rats<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>twice daily for 21 days</td> </tr> <tr> <td>Result:</td> <td>Completely stopped arthritis development in arthritis rats at 30 mg/kg.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Rats<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>1 mg/kg, 5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>IV and PO, single dosage</td> </tr> <tr> <td>Result:</td> <td>Exhibited a favorable pharmacokinetics profile with a clearance of 6 mL/min/kg and oral</td> </tr> </table>	Animal Model:	Rats <sup>[1]</sup>	Dosage:	30 mg/kg	Administration:	twice daily for 21 days	Result:	Completely stopped arthritis development in arthritis rats at 30 mg/kg.	Animal Model:	Rats <sup>[1]</sup>	Dosage:	1 mg/kg, 5 mg/kg	Administration:	IV and PO, single dosage	Result:	Exhibited a favorable pharmacokinetics profile with a clearance of 6 mL/min/kg and oral
Animal Model:	Rats <sup>[1]</sup>																
Dosage:	30 mg/kg																
Administration:	twice daily for 21 days																
Result:	Completely stopped arthritis development in arthritis rats at 30 mg/kg.																
Animal Model:	Rats <sup>[1]</sup>																
Dosage:	1 mg/kg, 5 mg/kg																
Administration:	IV and PO, single dosage																
Result:	Exhibited a favorable pharmacokinetics profile with a clearance of 6 mL/min/kg and oral																

---

bioavailability of 43%.

---

## REFERENCES

---

[1]. Chen Y, et al. Bicyclic pyrimidine compounds as potent IRAK4 inhibitors. Bioorg Med Chem Lett. 2022 Jul 18:128900.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA